Department of Infectious Diseases and Applied Immunology, IMSUT Hospital of the Institute of Medical Science, the University of Tokyo, Japan.
Division of Infectious Diseases, Advanced Clinical Research Center, Institute of Medical Science, the University of Tokyo, Japan.
Intern Med. 2022 Nov 15;61(22):3459-3462. doi: 10.2169/internalmedicine.0485-22. Epub 2022 Sep 6.
Persistent viral shedding or prolonged coronavirus disease 2019 (COVID-19) symptom is one of unresolved problem in immunocompromised individuals. We herein report an HIV/AIDS patient with Pneumocystis jirovecii pneumonia and prolonged COVID-19, possibly due to immune reconstitution inflammatory syndrome. His viral shedding and COVID-19 symptoms persisted for 39 days but were promptly resolved following sotrovimab monoclonal antibody therapy. This case suggests that prolonged COVID-19 and persistent viral shedding due to severe cellular immunodeficiency can occur in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) omicron infection and that sotrovimab is effective in the treatment of prolonged COVID-19 caused by omicron/BA.1.
持续性病毒脱落或长期的 2019 冠状病毒病(COVID-19)症状是免疫功能低下个体尚未解决的问题之一。本研究报告了一例 HIV/AIDS 合并卡氏肺孢子菌肺炎和长期 COVID-19 的患者,可能是由于免疫重建炎症综合征。他的病毒脱落和 COVID-19 症状持续了 39 天,但在接受 sotrovimab 单克隆抗体治疗后迅速得到缓解。该病例提示,在严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)奥密克戎感染患者中,严重细胞免疫缺陷可导致长期 COVID-19 和持续性病毒脱落,并且 sotrovimab 对奥密克戎/BA.1 引起的长期 COVID-19 治疗有效。